Taysha Gene Therapies (TSHA) Total Current Liabilities (2019 - 2026)

Taysha Gene Therapies has disclosed Total Current Liabilities across 8 years of filings, most recently posting $20.1 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $20.1 million, down 10.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.1 million (down 10.9% YoY), and the FY2025 annual result was $26.6 million, up 1.24% from the prior year.
• Total Current Liabilities came in at $20.1 million for Q1 2026 at Taysha Gene Therapies, down from $26.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $180.5 million in Q3 2023 to a low of $20.1 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $34.2 million (2024), against an average of $44.8 million.
• Across the five-year window, Total Current Liabilities surged 444.53% in 2023 and tumbled 83.74% in 2024, its largest moves.
• Taysha Gene Therapies' Total Current Liabilities stood at $62.8 million in 2022, then tumbled by 41.46% to $36.8 million in 2023, then dropped by 28.65% to $26.2 million in 2024, then rose by 1.24% to $26.6 million in 2025, then declined by 24.31% to $20.1 million in 2026.
• The last three Total Current Liabilities figures came in at $20.1 million (Q1 2026), $26.6 million (Q4 2025), and $28.6 million (Q3 2025), per Business Quant data.